PCM
PRME icon

Prelude Capital Management’s Prime Medicine PRME Stock Holding History

Prelude Capital Management’s Portfolio PRME Stock Details PRME Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-10,200
Closed -$35.4K – 1516
2025
Q4 		$35.4K Sell
10,200
-12,283
-55% -$54.6K ﹤0.01% 1249
2025
Q3 		$125K Sell
22,483
-18,805
-46% -$76.4K 0.01% 1025
2025
Q2 		$102K Buy
+41,288
New +$63.6K 0.01% 917

Other funds holding PRME

AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

Prelude Capital Management's PRME Position: Q1 2026 in Review

Prelude Capital Management sold out of Prime Medicine (PRME) in Q1 2026, closing a stake of 10,200 shares — an estimated $35.4K sold.

Prelude Capital Management first reported a position in PRME in Q2 2025 and held it in 3 quarters. The position peaked at $125K in Q3 2025. 192 funds tracked by Wall St. Rank hold PRME as of Q1 2026.

  • Prelude Capital Management reported no remaining Prime Medicine position as of Q1 2026 after selling out during the quarter.
  • Prelude Capital Management sold 10,200 Prime Medicine shares in Q1 2026, an estimated $35.4K.
  • Prelude Capital Management first reported a position in Prime Medicine in Q2 2025 and held it in 3 quarters.
  • Prelude Capital Management's Prime Medicine position peaked at $125K in Q3 2025.
  • 192 funds tracked by Wall St. Rank held Prime Medicine as of Q1 2026.

Based on Prelude Capital Management's 13F filing for Q1 2026, filed 15 May 2026.